GDS International to bring together executives at NG Pharma Summit 2012
Barton Creek Resort & Spa, Austin, Texas is booked for GDS International, from 23rd - 25th July 2012, for the NG Pharma Summit.
Like any other industry, today, the pharmaceutical sector is facing bigger challenges than ever before in discovery and development, clinical research and beyond. The cost of R&D is increasing at one end, and the number of new drugs approved is falling due to errors and/or lack of adequate evidence of the safety and effectiveness.
The Next Generation Pharmaceutical Summit will be a platform for the senior level pharmaceutical executives in the US pharmaceutical and biotechnology space to address core challenges in the Pharma sector; through interactive workshops, intimate panel discussions and networking, the senior level discovery and development executives from the sector will be able to procure and re-examine the R&D objectives.
Some of the topics to be covered during the summit, include- personalized medicine, key collaborations and strategic M&A activity within the sector, translational medicine, next generation imaging technologies, biomarker discovery and development, R&D and clinical trial partnership models, drug safety and pharmacovigilance, companion diagnostics and innovative information technology solutions.
Included within this year's delegation are Paul Chew, Chief Medical Officer of Sanaofi Aventis; Scott Treiber, VP Global Clinical Operations and Medical Affairs at Hospira; Rajesh Chopra, VP, Translational & Early Drug Development at Celgene; and Nestor Molfinio, VP, Clinical Development at Medlumme.
Like ever, the GDS summit will offer enormous value and a real opportunity to people to network with a range of companies that perhaps they might not otherwise meet. The synergy they achieve with the companies in attendance will be truly beneficial, for them.
For more details on NG Pharma Summit 2012, please refer: http://www.ngpsummit.com
Like any other industry, today, the pharmaceutical sector is facing bigger challenges than ever before in discovery and development, clinical research and beyond. The cost of R&D is increasing at one end, and the number of new drugs approved is falling due to errors and/or lack of adequate evidence of the safety and effectiveness.
The Next Generation Pharmaceutical Summit will be a platform for the senior level pharmaceutical executives in the US pharmaceutical and biotechnology space to address core challenges in the Pharma sector; through interactive workshops, intimate panel discussions and networking, the senior level discovery and development executives from the sector will be able to procure and re-examine the R&D objectives.
Some of the topics to be covered during the summit, include- personalized medicine, key collaborations and strategic M&A activity within the sector, translational medicine, next generation imaging technologies, biomarker discovery and development, R&D and clinical trial partnership models, drug safety and pharmacovigilance, companion diagnostics and innovative information technology solutions.
Included within this year's delegation are Paul Chew, Chief Medical Officer of Sanaofi Aventis; Scott Treiber, VP Global Clinical Operations and Medical Affairs at Hospira; Rajesh Chopra, VP, Translational & Early Drug Development at Celgene; and Nestor Molfinio, VP, Clinical Development at Medlumme.
Like ever, the GDS summit will offer enormous value and a real opportunity to people to network with a range of companies that perhaps they might not otherwise meet. The synergy they achieve with the companies in attendance will be truly beneficial, for them.
For more details on NG Pharma Summit 2012, please refer: http://www.ngpsummit.com
